Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
DT heads into its November 5 earnings with analysts raising targets, short sellers rebuilding positions, and options traders taking out more downside cover than they have in months.
The Street has been notably constructive. UBS raised its target to $74 from $65 last week while keeping a Buy rating. Oppenheimer lifted to $71 from $60 the week before. Needham upgraded outright to Buy. The direction of travel is clear: targets have moved from the mid-$50s to the mid-$60s and above across most of the covering firms over the past six weeks, following August results that sent the stock 6.7% higher on the day. The mean consensus target of roughly $60 barely clears the current price of $59.81, which reflects how quickly the stock has moved. DT has gained 15% over the past month alone, and the Street's target revisions are still catching up. The bull case rests on AI observability traction exceeding 1,000 customers, annualised log consumption nearly doubling to around $200 million over two quarters, and the Arize acquisition adding roughly $40 million of ARR. Bears point to an increasingly crowded market, long sales cycles, and valuation risk if growth disappoints.
Short interest is rising, but at this stage it reads more like cautious trimming of positions than outright conviction against the stock. Short interest as a percentage of free float has climbed to 4.75%, up 46% over the past month in share terms, a material increase but still a modest absolute level. The borrow market remains extremely loose. Availability is running at roughly 1,600% of current short interest, meaning there are about 238 million shares available to lend against the 14 million currently borrowed. That is close to its one-year low on availability tightness, the opposite of squeeze territory. Cost to borrow is 0.43%, up about 13% on the week but still a fraction of what would signal stress. The ORTEX short score has edged up to 38.5, its highest of the past two weeks, consistent with the rise in positioned shorts, though it remains well below any threshold that would mark this as a high-conviction short.
Options positioning has turned more hedged than usual. The put/call ratio hit 0.34 on Wednesday, its highest single-day reading in several weeks outside the September 28 spike to 0.55, and sits about 0.9 standard deviations above its 20-day average of 0.27. That puts it closer to the cautious end of its recent range without reaching the 52-week high of 0.55. The pattern is consistent with investors buying some protection into the November earnings date after a sharp run-up, rather than an outright defensive posture.
On the institutional register, Starboard Value holds an 8.87 million share stake representing just over 3% of shares, having built the entire position in the quarter ending June 30. Pictet Asset Management is notable on the activist register: it filed a Schedule 13D/A on September 25, with its stake trimmed to 4.9% from 5.0%. That 13D filing classification matters. An investor on the 13D register has disclosed activist intent, though Pictet's most recent move is a slight reduction. As the disclosure note requires: these positions are as-last-disclosed around the 5% threshold, and a holder can fall below 5% without a further filing. The only material insider activity in the period was the CTO, Bernd Greifeneder, selling 50,000 shares on September 18 at $57.21, a $2.9 million transaction executed under a pre-arranged 10b5-1 plan. Planned sales carry less signal than discretionary ones, but the direction is notable at current levels.
The next print is on November 5, 28 days away. With the stock trading essentially at the consensus target, the debate into that date centres less on whether observability demand is growing and more on whether the pace of AI-driven expansion can justify a valuation that has moved decisively ahead of where analysts were just six weeks ago.
See the live data behind this article on ORTEX.
Open DT on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
